Fully Oral Regimen with Decitabine and Cedazuridine Plus Venetoclax: a New Step Forward for Older or Unfit Patients with Acute Myeloid Leukaemia
The Lancet Haematology(2024)
摘要
Over the past 10 years, the therapeutic options for older or unfit patients with acute myeloid leukaemia have greatly improved thanks to the introduction of demethylating agents into clinical practice, first as monotherapy and then in combination with the BCL-2 inhibitor venetoclax (demethylating agents–venetoclax).1–6 Thanks to these drugs, the probability of overall survival of older and unfit patients with acute myeloid leukaemia (who are ineligible for intensive chemotherapy) has increased from a few weeks to months or even years, in responsive cases.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要